» Articles » PMID: 21498634

Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism

Overview
Journal Cancer Res
Specialty Oncology
Date 2011 Apr 19
PMID 21498634
Citations 154
Authors
Affiliations
Soon will be listed here.
Abstract

Trastuzumab shows remarkable efficacy in treatment of ErbB2-positive breast cancers when used alone or in combination with other chemotherapeutics. However, acquired resistance develops in most treated patients, necessitating alternate treatment strategies. Increased aerobic glycolysis is a hallmark of cancer and inhibition of glycolysis may offer a promising strategy to preferentially kill cancer cells. In this study, we investigated the antitumor effects of trastuzumab in combination with glycolysis inhibitors in ErbB2-positive breast cancer. We found that trastuzumab inhibits glycolysis via downregulation of heat shock factor 1 (HSF1) and lactate dehydrogenase A (LDH-A) in ErbB2-positive cancer cells, resulting in tumor growth inhibition. Moreover, increased glycolysis via HSF1 and LDH-A contributes to trastuzumab resistance. Importantly, we found that combining trastuzumab with glycolysis inhibition synergistically inhibited trastuzumab-sensitive and -resistant breast cancers in vitro and in vivo, due to more efficient inhibition of glycolysis. Taken together, our findings show how glycolysis inhibition can dramatically enhance the therapeutic efficacy of trastuzumab in ErbB2-positive breast cancers, potentially useful as a strategy to overcome trastuzumab resistance.

Citing Articles

Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer.

Madoz-Gurpide J, Serrano-Lopez J, Sanz-Alvarez M, Morales-Gallego M, Rodriguez-Pinilla S, Rovira A Int J Mol Sci. 2025; 26(4).

PMID: 40004024 PMC: 11855744. DOI: 10.3390/ijms26041559.


Research progresses and hotspots on glucose metabolic reprogramming in breast cancer: a bibliometric analysis over the past two decades.

Huang L, Zhao W, Sun L, Niu D, Zhu X, Jin C Front Oncol. 2025; 14:1493996.

PMID: 39876898 PMC: 11772165. DOI: 10.3389/fonc.2024.1493996.


Metabolomics-Driven Biomarker Discovery for Breast Cancer Prognosis and Diagnosis.

Kaur R, Gupta S, Kulshrestha S, Khandelwal V, Pandey S, Kumar A Cells. 2025; 14(1.

PMID: 39791706 PMC: 11720085. DOI: 10.3390/cells14010005.


Intrathecal lactate dehydrogenase A inhibitors FX11 and oxamate alleviate chronic constriction injury-induced nociceptive sensitization through neuroinflammation and angiogenesis.

Cheng H, Chen N, Chen W, Wu Z, Sun Y, Teng W J Headache Pain. 2024; 25(1):207.

PMID: 39587478 PMC: 11590346. DOI: 10.1186/s10194-024-01916-x.


Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.

PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.


References
1.
Lu C, Wyszomierski S, Tseng L, Sun M, Lan K, Neal C . Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007; 13(19):5883-8. DOI: 10.1158/1078-0432.CCR-06-2837. View

2.
Hsu P, Sabatini D . Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7. DOI: 10.1016/j.cell.2008.08.021. View

3.
Tan M, Yu D . Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007; 608:119-29. DOI: 10.1007/978-0-387-74039-3_9. View

4.
Junttila T, Akita R, Parsons K, Fields C, Lewis Phillips G, Friedman L . Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009; 15(5):429-40. DOI: 10.1016/j.ccr.2009.03.020. View

5.
Ramanathan A, Wang C, Schreiber S . Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A. 2005; 102(17):5992-7. PMC: 1087961. DOI: 10.1073/pnas.0502267102. View